Thermon Group Holdings (NYSE: THR) reported earnings on Aug. 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q1), Thermon Group Holdings missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share increased.

Margins increased across the board.

Revenue details
Thermon Group Holdings logged revenue of $67.2 million. The eight analysts polled by S&P Capital IQ looked for sales of $69.7 million on the same basis. GAAP reported sales were 4.0% higher than the prior-year quarter's $64.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.23. The eight earnings estimates compiled by S&P Capital IQ averaged $0.21 per share. GAAP EPS were $0.21 for Q1 versus -$0.18 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 49.6%, 10 basis points better than the prior-year quarter. Operating margin was 21.6%, 2,240 basis points better than the prior-year quarter. Net margin was 9.8%, 1,750 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $76.5 million. On the bottom line, the average EPS estimate is $0.26.

Next year's average estimate for revenue is $301.1 million. The average EPS estimate is $1.09.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 17 members out of 17 rating the stock outperform, and members rating it underperform. Among five CAPS All-Star picks (recommendations by the highest-ranked CAPS members), five give Thermon Group Holdings a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thermon Group Holdings is outperform, with an average price target of $23.64.